We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

333 hedge funds and large institutions have $6.5B invested in Intra-Cellular Therapies Inc. in 2023 Q4 according to their latest regulatory filings, with 73 funds opening new positions, 109 increasing their positions, 112 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

170% more first-time investments, than exits

New positions opened: 73 | Existing positions closed: 27

111% more call options, than puts

Call options by funds: $58.1M | Put options by funds: $27.5M

43% more capital invested

Capital invested by funds: $4.54B → $6.5B (+$1.96B)

25% more funds holding in top 10

Funds holding in top 10: 8 → 10 (+2)

14% more funds holding

Funds holding: 292 → 333 (+41)

3% less repeat investments, than reductions

Existing positions increased: 109 | Existing positions reduced: 112

Holders
333
Holders Change
+41
Holders Change %
+14.04%
% of All Funds
4.85%
Holding in Top 10
10
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+25%
% of All Funds
0.15%
New
73
Increased
109
Reduced
112
Closed
27
Calls
$58.1M
Puts
$27.5M
Net Calls
+$30.6M
Net Calls Change
+$30.4M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$130M
2
Morgan Stanley
Morgan Stanley
New York
+$89.1M
3
BlackRock
BlackRock
New York
+$39M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$34.8M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$31.9M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$62.2M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$35.1M
3
DTC
Deep Track Capital
Connecticut
-$34.5M
4
Pictet Asset Management
Pictet Asset Management
Switzerland
-$23.8M
5
ITP
Iron Triangle Partners
Connecticut
-$17.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
AGP
126
Artia Global Partners
Florida
$2.98M – – –
Squarepoint
127
Squarepoint
New York
$2.95M -$2.48M -43,065 -51%
CM
128
Caption Management
Oklahoma
$2.86M +$2.3M +39,997 New
GC
129
Guggenheim Capital
Illinois
$2.85M +$1.29M +22,356 +128%
Citigroup
130
Citigroup
New York
$2.8M +$1.68M +29,120 +290%
AQR Capital Management
131
AQR Capital Management
Connecticut
$2.77M +$505K +8,774 +29%
Citadel Advisors
132
Citadel Advisors
Florida
$2.55M -$2.85M -49,610 -58%
1CM
133
1492 Capital Management
Wisconsin
$2.53M +$20.8K +361 +1%
OAM
134
Oppenheimer Asset Management
New York
$2.49M +$21.5K +374 +1%
Natixis Advisors
135
Natixis Advisors
Massachusetts
$2.43M +$147K +2,554 +8%
Stifel Financial
136
Stifel Financial
Missouri
$2.41M +$7.13K +124 +0.4%
EAM
137
EFG Asset Management
Oregon
$2.32M -$46.3K -804 -2%
JFG
138
Jefferies Financial Group
New York
$2.08M +$1.66M +28,840 +18,025%
EAM
139
Exome Asset Management
New York
$2.03M +$1.63M +28,300 New
KCM
140
Kennedy Capital Management
Missouri
$1.96M -$141K -2,450 -8%
PFC
141
Phocas Financial Corp
California
$1.95M +$1.57M +27,210 New
State Board of Administration of Florida Retirement System
142
State Board of Administration of Florida Retirement System
Florida
$1.92M – – –
SO
143
STRS Ohio
Ohio
$1.88M -$92K -1,600 -6%
BMSSC
144
B. Metzler seel. Sohn & Co
Germany
$1.86M +$21.5K +374 +1%
AWA
145
Arete Wealth Advisors
Illinois
$1.84M +$4.66K +81 +0.3%
BCI
146
Brinker Capital Investments
Pennsylvania
$1.8M -$126K -2,193 -8%
OPS
147
Orion Portfolio Solutions
Nebraska
$1.8M -$126K -2,193 -8%
Hudson Bay Capital Management
148
Hudson Bay Capital Management
Connecticut
$1.79M -$575K -10,000 -29%
MCM
149
Moore Capital Management
New York
$1.79M +$1.44M +25,000 New
Marshall Wace
150
Marshall Wace
United Kingdom
$1.74M -$1.08M -18,699 -44%
4 5
6
7 8

ITCI Hedge Fund Activity: Q4 2023 in Review

333 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2023, worth a combined $6.5B — up 43% from $4.54B a quarter earlier.

Buyers outnumbered sellers: 73 funds opened new ITCI positions and 27 closed out — a net gain of 46 holders — while 109 added to existing stakes and 112 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $130M. The largest seller was Woodline Partners, exiting entirely with an estimated $62.2M sold.

  • 333 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2023, up from 292 in Q3 2023.
  • Funds reported $6.5B of Intra-Cellular Therapies Inc. stock for Q4 2023, up 43% quarter-over-quarter.
  • 73 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2023 and 27 closed out, a net change of +46 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q4 2023 was Avoro Capital Advisors, an estimated $130M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q4 2023 was Woodline Partners, an estimated $62.2M sold.

Based on aggregated 13F filings for Q4 2023.